To include your compound in the COVID-19 Resource Center, submit it here.

Lucentis ranibizumab regulatory update

A panel from the U.K.'s NICE will meet on Oct. 4 to hear an appeal from Novartis on a July

Read the full 203 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE